Avidity Biosciences' Delpacibart Etedesiran Receives Orphan Drug Designation in Japan for Myotonic Dystrophy Type 1 Treatment Avidity Biosciences' delpacibart etedesiran secures Orphan Drug designation in Japan for the treatment of Myotonic Dystrophy type 1. This milestone could redefine care options.

Avidity Biosciences' Delpacibart Etedesiran Receives Orphan Drug Designation in Japan for Myotonic Dystrophy Type 1 Treatment #Japan #Tokyo #Myotonic_Dystrophy #Avidity_Biosciences #delpacibart

Avidity Biosciences Advances Delpacibart Braxlosiran in Clinical Trial for Facioscapulohumeral Muscular Dystrophy Avidity Biosciences has finished enrolling participants in their Phase 1/2 FORTITUDE trial for delpacibart braxlosiran, targeting Facioscapulohumeral Muscular Dystrophy. Positive data expected.

Avidity Biosciences Advances Delpacibart Braxlosiran in Clinical Trial for Facioscapulohumeral Muscular Dystrophy #United_States #San_Diego #Avidity_Biosciences #delpacibart #FSHD